F. HoffmannLa Roche Ltd European Commission approves Roche\'s new Tecentriqbased combination therapy as an initial treatment for most common form of advanced lung cancer

F. Hoffmann-La Roche Ltd: European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC)Decision based on data showing that...

More From BioPortfolio on "F. Hoffmann-La Roche Ltd: European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer"